Paul Beswick

1.7k citations

38 papers · 1.0k indexed · h-index 20

Co-authors: Simon E. Ward Michael C. Willis David A. Widdowson Robert J. Gleave D. I. C. SCOPES Jason Brown Oliver N. F. King Ganesha Rai
Topics: Antimicrobial Peptides and Activities (5 papers)Monoclonal and Polyclonal Antibodies Research (5 papers)Synthesis and Biological Evaluation (5 papers)
Cited by: Organic Chemistry Physiology Biological Psychiatry
Journals: Angewandte Chemie International Edition PLoS ONE Cancer Research
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Paul Beswick

37 papers receiving 1.0k citations

Peers

Countries citing papers authored by Paul Beswick

Since Specialization

Citations

This map shows the geographic impact of Paul Beswick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Beswick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Beswick more than expected).

Fields of papers citing papers by Paul Beswick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Beswick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Beswick. The network helps show where Paul Beswick may publish in the future.

Co-authorship network of co-authors of Paul Beswick

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Beswick. A scholar is included among the top collaborators of Paul Beswick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Beswick. Paul Beswick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and chemical optimisation of a potent, Bi-cyclic antimicrobial inhibitor of Escherichia coli PBP3 2025 ·Communications Biology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Steven J. Stanway,(unknown),(unknown),Katerine Van Rietschoten,Dom Bellini,David I. Roper,Adrian J. Lloyd,Christopher G. Dowson,Michael J. Skynner,Paul Beswick,Michael J. Dawson	1
2	Investigating Penetration and Antimicrobial Activity of Vector-Bicycle Conjugates 2024 ·ACS Infectious Diseases ·(unknown),(unknown),(unknown),(unknown),(unknown),Steven J. Stanway,Michael J. Dawson,Michael J. Skynner,Paul Beswick	1
3	Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors 2024 ·Cancer Research ·Stephen J. Walsh,Johanna Lahdenranta,Philip Huxley,Gemma Mudd,Gavin Bennett,Amy Brown,(unknown),Liuhong Chen,(unknown),(unknown),(unknown),Mike Rigby,Olga Burenkova,Phil Jeffrey,Paul Beswick,Michael J. Skynner,Nicholas Keen	0
4	Structure-Guided Chemical Optimization of Bicyclic Peptide (Bicycle) Inhibitors of Angiotensin-Converting Enzyme 2 2023 ·Journal of Medicinal Chemistry ·(unknown),Steven J. Stanway,(unknown),Yuliya Demydchuk,G.A. Bezerra,Simone Pellegrino,Liuhong Chen,P. Brear,Aleksei Lulla,Marko Hyvönen,Paul Beswick,Michael J. Skynner	3
5	BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors 2022 ·Molecular Cancer Therapeutics ·Michael Rigby,Gavin Bennett,Liuhong Chen,Gemma Mudd,(unknown),Paul Beswick,Katerine Van Rietschoten,(unknown),(unknown),Amy Brown,Peter U. Park,Carly Campbell,Eric Haines,Johanna Lahdenranta,Michael J. Skynner,Phil Jeffrey,Nicholas Keen,(unknown)	41
6	Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer 2022 ·Journal of Medicinal Chemistry ·Gemma Mudd,(unknown),Liuhong Chen,Katerine Van Rietschoten,(unknown),(unknown),Amy Brown,(unknown),(unknown),Peter U. Park,Phil Jeffrey,Mike Rigby,Paul Beswick	58
7	A challenge finding P2X1 and P2X4 ligands 2019 ·Neuropharmacology ·Paul Beswick,(unknown),(unknown),Michael Paradowski,(unknown),Martin Lochner,Ruth D. Murrell‐Lagnado,Andrew J. Thompson	5
8	Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models 2019 ·Cancer Research ·Mike Rigby,Paul Beswick,Gemma Mudd,Katerine Van Rietschoten,Liuhong Chen,(unknown),(unknown),Amy Brown,(unknown),Gavin Bennett,Phil Jeffrey,Peter U. Park,María Koehler,Nicholas Keen	6
9	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase 2017 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),Trevor Askwith,John Atack,Paul Beswick,(unknown),Michael Paradowski,Lewis E. Pennicott,Srinivasa P. S. Rao,Gareth Williams,Simon E. Ward	15
10	Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors 2016 ·European Journal of Medicinal Chemistry ·(unknown),Paul Beswick,(unknown),Lueacha Tabtimmai,(unknown),(unknown),(unknown),(unknown),Irina Chuckowree,Supa Hannongbua,Simon E. Ward,Kiattawee Choowongkomon,M. Paul Gleeson	24
11	Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor 2011 ·Bioorganic & Medicinal Chemistry Letters ·Robert J. Young,W. Alderton,(unknown),Paul Beswick,David Brown,(unknown),(unknown),John Dawson,C. Hamlett,Simon T. Hodgson,(unknown),Richard G. Knowles,Linda Russell,(unknown),James M. Woolven	2
12	Synthesis and structure–activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Alexander J. Stevens,(unknown),Anton D. Michel,Daryl S. Walter,D.J.G. Davies,David G. Livermore,Elena Fonfría,Emmanuel H. Demont,(unknown),Pam Theobald,Paul Beswick,Robert J. Gleave,Shilina Roman,Stefan Senger	21
13	Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Paul Beswick,Andy Billinton,(unknown),David K. Dean,Elena Fonfría,Robert J. Gleave,Stephen J. Medhurst,Anton D. Michel,(unknown),Sadhana Patel,Shilina Roman,Tiziana Scoccitti,Beverley Smith,Jon G.A. Steadman,Daryl S. Walter	25
14	Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X7 antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Robert J. Gleave,Daryl S. Walter,Paul Beswick,Elena Fonfría,Anton D. Michel,Shilina Roman,Sac-Pham Tang	25
15	Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors 2010 ·PLoS ONE ·Oliver N. F. King,(unknown),Masaaki Sakurai,Akane Kawamura,Nathan R. Rose,Stanley S. Ng,Amy Quinn,Ganesha Rai,Bryan T. Mott,Paul Beswick,Robert J. Klose,Udo Oppermann,Ajit Jadhav,Tom D. Heightman,David J. Maloney,Christopher J. Schofield,Anton Simeonov	173
16	Structure–activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor 2010 ·Bioorganic & Medicinal Chemistry Letters ·Paul Beswick,Andy Billinton,(unknown),David K. Dean,Elena Fonfría,Robert J. Gleave,Stephen J. Medhurst,Anton D. Michel,(unknown),Sadhana Patel,Shilina Roman,(unknown),Stefan Senger,Alexander J. Stevens,Daryl S. Walter	23
17	2-Amino-5-aryl-pyridines as selective CB2 agonists: Synthesis and investigation of structure–activity relationships 2009 ·Bioorganic & Medicinal Chemistry Letters ·Robert J. Gleave,Paul Beswick,Andrew J. Brown,Gerard M.P. Giblin,Carl Haslam,David G. Livermore,(unknown),Neville Nicholson,Lee W. Page,Brian P. Slingsby,Martin E. Swarbrick	9
18	The role of the cylooxygenase pathway in nociception and pain 2006 ·Seminars in Cell and Developmental Biology ·Sharon Bingham,Paul Beswick,David Blum,Norman M. Gray,Iain P. Chessell	34
19	Chelation‐Controlled Intermolecular Hydroacylation: Direct Addition of Alkyl Aldehydes to Functionalized Alkenes 2003 ·Angewandte Chemie International Edition ·Michael C. Willis,(unknown),Paul Beswick	114
20	Synthetic applications of lithiated tricarbonyl-η⁶-arenechromium(0) complexes: copper and palladium catalysed substitutions 1984 ·Journal of the Chemical Society Chemical Communications ·Paul Beswick,(unknown),(unknown),David A. Widdowson	16

About Paul Beswick

Paul Beswick is a scholar working on Physiology, Microbiology and Organic Chemistry, having authored 38 papers that have together received 1.0k indexed citations. Recurring topics across this work include Antimicrobial Peptides and Activities (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Synthesis and Biological Evaluation (5 papers). The work is most often cited by research in Organic Chemistry (471 citations), Physiology (74 citations) and Biological Psychiatry (32 citations). Paul Beswick has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Simon E. Ward, Michael C. Willis, David A. Widdowson, Robert J. Gleave, D. I. C. SCOPES, Jason Brown, Oliver N. F. King, Ganesha Rai, J. W. CLITHEROW and Robert J. Klose. Their work appears in journals such as Angewandte Chemie International Edition, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact